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VENOUS THROMBOEMBOLISM 
RISK FACTORS AND PRACTICES OF 
PROPHYLAXIS
Endorse Study Results in Portugal 
Recebido em: 28 de Julho de 2010
Aceite em: 25 de Outubro de 2010
Background: Venous thromboembolism (VTE) risk assessment is a cornerstone for the achie-
vement of best practices and outcomes. Epidemiologic data and practices related to venous 
thromboprophylaxis as considered by the global ENDORSE study, (Epidemiologic International 
Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital 
Care Setting), enrolled 68,183 patients from 32 countries, in wich Portugal. Within ENDORSE, 
data from all participant countries analyzed to determine their risk of VTE and to evaluate the 
suitability of prophylaxis.
Methods: European patients were enrolled from randomly selected hospitals in Portugal (Eu-
ropean Hospital Register), according to ENDORSE study inclusion/exclusion criteria. The 
Seventh ACCP evidence-based consensus guidelines were employed to evaluate VTE risk and 
prophylaxis use.
Results: From a total of 3,145 beds assessed, 2,183 were considered eligible and 1,632 met all 
criteria. Of these, 860 (52.7%; 95% CI 50.3-55.1) were at risk of VTE: 525 surgical patients 
(68.9%; 95% CI 65.5-72.1) and 335 medical patients (38.5%; 95% CI 35.3-41.2). The rate of 
prophylaxis according to ACCP guidelines in overall patients at risk was 58.5% (503 patients). 
The prophylaxis rate for VTE was 59% (310 patients) in surgical patients and 57.6% (n=193) 
in medical patients. 39.7% of surgical patients and 39.4 % of medical patients who did not 
meet the criteria for prophylaxis were also on prophylaxis with an anticoagulant, which was 
considered to be inappropriate. 
Conclusions: More than a half of these hospitalized patients in Portugal were deemed at risk 
of VTE and less than two-thirds of  them received appropriate prophylaxis. New strategies are 
required for implementation of venous thromboprophylaxis in Portuguese hospitals.
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Resultados do Estudo ENDORSE em Portugal, Práticas de Tromboprofilaxia
Introdução: A avaliação de risco de tromboembolismo venoso (TEV) é determinante para 
o desenvolvimento de melhores práticas de prevenção e obtenção melhores indicadores de 
resultado. Os dados epidemiológicos recolhidos no estudo ENDORSE Global ou no caso 
dos dados de país serem estatisticamente significativos para o mesmo, são factores chave 
para o conhecimento da avaliação e gestão clínica do TEV assim como para a tomada de 
R E S U M O
S U M M A R Y 
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INTRODUCTION
Venous thromboembolism is a well known problem 
in hospitalized patients1,2 and a very significant 
cause of death in Europe3 and in the USA4-6. Despite 
guidelines and recommendations, clinicians are prone 
to underestimate the risk of venous thromboembolism 
(VTE) as a cause for fatal outcome in hospitalized 
patients as well as in the outpatient setting7.
The confidence in evidence-based medicine and the 
need for developing standards for practice, seems quite 
new according to current compliance and the rate of 
implementation of recommendations and guidelines8. 
Doctors act in contradiction to well and long time 
documented evidence of recommendations in this field, 
with evident detriment of patient’s safety.
In Portugal, International Guidelines are generally 
well accepted and in particular, Scientific Societies 
directly assume them. The direct evidence and clear 
illustration of the problem has been demonstrated 
by ENDORSE, the largest international prophylaxis 
evaluation study ever performed, in randomly selected 
hospitals around the world9. The main objectives 
were to identify patients at risk for VTE and the 
proportion of patients who receive appropriate VTE 
prophylaxis according to the American College of 
Chest Physicians9(ACCP) evidence-based consensus 
guidelines.
The aim of the current publication is to call attention 
to Portugal-specific ENDORSE data, namely inpatients 
at risk of VTE and current practices of prophylaxis.
METHODS
The methodology of the global ENDORSE study 
was followed10.
Patients were enrolled from nine randomly selected 
hospitals in Portugal, (Figure 1) identified from eligible 
hospitals on the European Hospital Register11. 
All randomized hospitals were public, providing 
general, acute care; three hospitals were University-
linked. At the end of 2006, the Portuguese National 
Health Service comprised 58 public, multispecialty 
hospitals, providing 20,615 acute care beds1 for a 
novas atitudes perante a doença. O objectivo da actual análise é a avaliação dos 
dados de Portugal no ENDORSE, assim como sensibilizar para  o risco de TEV 
determinado nos doentes internados nos hospitais portugueses e a adequação da 
profilaxia nessa população.
Métodos: A selecção dos doentes obedeceu aos critérios de inclusão / exclusão do 
estudo ENDORSE em nove hospitais Portugueses aleatoriamente seleccionados a 
partir do Registo Europeu dos Hospitais. Para avaliar o risco de TEV e profilaxias 
usadas serviram como referência as recomendações da sétima revisão de consensus 
sobre tromboembolismo venoso do American College of Chest Physicians. 
Resultados: Num universo de 3145 camas de internamento avaliadas, 2183 foram 
consideradas elegíveis e 1632 preencheram todos os critérios de inclusão. Destes 
últimos 1632 doentes apenas 860 (52,7%, 95% CI 50,3-55,1) estavam em risco de 
TEV: 525 doentes cirúrgicos (68,9% 95% CI 65,5-72,1) e 335 doentes médicos 
(38,5%, 95% CI 35,3-41,2). A taxa de profilaxia (de acordo com as recomendações 
do ACCP) foi de 58,5% (503 doentes), que corresponde a 59% (310 doentes) dos 
doentes cirúrgicos e 57,6% (n = 193) dos doentes médicos. Dos doentes cirúrgicos 
(39,7%) e dos doentes médicos (39,4%) que não preenchiam os critérios para a 
profilaxia foram, também, submetidos a profilaxia com anticoagulante considerada 
como inadequada, à luz das recomendações ACCP.
Conclusões: Tendo por base os dados do Estudo ENDORSE relativamente a 
Portugal, mais da metade dos nossos doentes internados estão em risco de TEV e 
menos de dois terços recebem a profilaxia adequada. Neste contexto alerta-se para 
a exposição dos doentes a riscos desnecessários e para a necessidade de definição 
de novas estratégias de segurança tendentes uma adequada tromboprofilaxia venosa 
nos hospitais Portugueses. 
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population of 10,6 million. The median number of beds 
per hospital was 351 (range 95–615 beds). No reference 
to hospital VTE protocols was found, despite some 
references to individual service protocols. 
The small size data of individual hospitals within 
the country invalidated an inter-hospital evaluation of 
variation practices in prophylaxis.
Inclusion criteria: Patients ≥40 years-old and 
admitted to a medical ward, or who were ≥18 years-
old and admitted in a surgical ward or admitted for a 
nonsurgical trauma, were enrolled to assess their risk 
of VTE. Patients were considered ineligible or excluded 
from the study, if their chart was unavailable, if were 
admitted to an ineligible ward, or if they were admitted 
for treatment of VTE. Enrolled patient charts were 
reviewed, including medical history, current medical 
conditions, type of surgery, initiation and type of VTE 
prophylaxis.
Primary objectives: Risk assessment for VTE. 
Enrolled patients were assessed for risk of VTE in 
accordance with the 2004 ACCP guidelines, including 
acutely ill medical patients and those admitted for 
major trauma or undergoing a major surgical procedure 
requiring general or epidural anesthesia for at least 45 
minutes. Surgical patients were first assessed, for age, 
type of surgery, and duration of anesthesia, and then 
classified as being at highest, high, moderate, or low 
risk for VTE, according to the ACCP guidelines.
Secondary objective: VTE prophylaxis. 
The use of recommended types of VTE prophylaxis 
received by at-risk patients was defined according 
to specific recommendation from the 2004 ACCP 
guidelines for the different types of patients at risk, and, 
designated as appropriate prophylaxis (ApP). Patients 
considered not at risk using the ACCP consensus 
guidelines and on pharmacological prophylaxis were 
considered to be submitted to inappropriate prophylaxis 
(InP).
Patients were considered to have major bleeding, 
if they developed during hospitalization any of the 
following: intracranial hemorrhage, hepatic impairment, 
bleeding at hospital admission, active gastroduodenal 
ulcer, or a known bleeding disorder, or were considered to 
have a contraindication to anticoagulation prophylaxis. 
Data from all eligible charts, in selected wards, at 
each hospital, was completed by medical interns and 
hospital investigators within 10 days, and collected 
by Keypoint1 team. Extracted data included: patient 
demographics, admission and post-admission diagnoses, 
risk factors associated with VTE (defined in the ACCP 
guidelines). Risk factors for bleeding, hospitalization 
duration, and type of VTE prophylaxis (defined in the 
ACCP guidelines), were also evaluated. Only the total 
patients in the country were be considered, due to the 
small number of patients included by hospital and by 
pathology.
Statistical Analysis:  Quantitative data were 
summarized as median and interquartile range (IQR). 
Categorical data were summarized into number and 
percentage of the population. Rates were calculated 
from individual patient data. Rate comparisons were 
performed using Tests for Proportions Comparison; 95% 
CI were calculated for the main outcomes. A significance 
level of 0.05 was assumed for all statistical calculations.
RESULTS
Global ENDORSE data showed that of the 57,570 
patients included in the final analysis, 21,219 (37%) 
were surgical and 36,351 (63%) were medical patients. 
64% of the surgical patients and 42% of the medical 
patients were deemed to be at risk of VTE according to 
ACCP criteria. ACCP recommended prophylaxis was 
prescribed to 58.5% of the surgical patients, and to 
39.5% of the medical patients at risk of VTE (proportion 
surgical / medical at risk = 2.2)10. These findings fulfilled 
a need for country-specific data extracted from the 
global data.
Portugal study population
The number of beds assessed in Portugal, and reasons 
for exclusion of patients assessment, are shown in Figure 
2, together within the number of evaluable medical and Fig. 1– Hospital distribution – Portugal, 10.6 million inhabitants
954www.actamedicaportuguesa.com
Fig. 2 - Patient sample population and reasons for exclusion
Table 1– Demographic and anthropometric characteristics of the patients studied
 Portuguese Patients evaluated Portuguese patients at risk o VTE
Surgical 
patients
Medical 
patients Total
Surgical 
patients
Medical 
patients All Risk
(n=762) (n=870) (n=1,632) (n=525) (n=335) (n=860)
Sex (female) 362/729 (49.7%)
377/846 
(44.5%)
739 
(45.3%)
263/521 
(50.5%)
144/333 
(43.2%) 407(47.7%)
Median Age (years) 734 (68) 853 (72) 1587(70) 525 (68) 335 (75) 860(71)
Median Body Mass Index
(BMI)Kg/m2 124 (26.9) 50 (25.1) 174(26.0) 103 (26.9) 19 (27.4) 122((26.9)
Median Length of hospitalization up 
to survey date 726 (6) 847 (7) 1573(6) 518 (6) 334 (8) 852 (7)
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Table 3- Risk Factors for Venous Thromboembolism
 Risk Factors for VTE
Surgical
(525)
Medical 
(335)
All
(860)
n % n % n %
C
on
di
tio
ns
 B
ef
or
e 
H
os
pi
ta
l a
dm
is
si
on
 Chronic pulmonary disease 16 3.9% 61 20.1% 77 10.8%
 Chronic heart failure 10 2.5% 49 16.1% 59 8.3%
 Obese (based on physician’s note) 24 5.9% 21 6.9% 45 6.3%
 Varicose veins or venous insufficiency 30 7.4% 9 3.0% 39 5.5%
 Long term immobility 6 1.5% 23 7.6% 29 4.1%
 Previous venous thromboembolism 0 0.0% 5 1.6% 5 0.7%
 Contraceptives 5 1.2% 0 0.0% 5 0.7%
 Thrombophilia (laboratory documented) 0 0.0% 1 0.3% 1 0.1%
 Post-menopausal hormone replacement therapy 1 0.2% 0 0.0% 1 0.1%
 Pregnancy (within 3 months) 1 0.2% 0 0.0% 1 0.1%
C
on
di
tio
ns
 p
re
se
nt
 a
t h
os
pi
ta
l a
dm
is
si
on
 Other medical condition 173 33.0% 35 10.0% 208 24.2%
 Pulmonary infection 13 2.5% 153 45.7% 166 19.3%
 Other cardiovascular disease 66 12.6% 67 20.0% 133 15.5%
 Malignancy (active) 90 17.1% 29 8.7% 119 13.8%
 GI/Hepatobiliary 72 13.7% 20 6.0% 92 10.7%
 Infection (non-respiratory) 45 8.6% 36 10.7% 81 9.0%
 Endocrine/Metabolic 40 7.6% 27 8.1% 67 7.8%
 Acute non-infectious respiratory disease 7 1.3% 53 15.8% 60 7.0%
 Acute heart failure (NYHA Class III or IV) 1 0.2% 51 15.2% 52 6.0%
 Neurologic 28 5.3% 24 7.2% 52 6.0%
 Renal 16 3.0% 19 5.7% 35 4.1%
 Ischemic stroke 0 0.0% 34 10.1% 34 4.0%
 Hematologic disease 15 2.9% 13 3.9% 28 3.3%
 Hemorrhagic stroke 2 0.4% 17 5.1% 19 2.2%
 Rheumatologic or inflammatory 14 2.7% 2 0.6% 16 1.9%
A
dd
iti
on
al
 r
is
k 
fa
ct
or
s f
or
 
V
T
E
 D
U
R
IN
G
 h
os
pi
ta
l 
ep
is
od
e
 Complete immobilization 151 28.8% 106 31.6% 257 29.9%
 Immobile with bathroom privileges 49 9.3% 45 13.4% 94 10.9%
 Mechanical ventilation 34 6.5% 45 13.4% 79 9.2%
 Central venous catheter 46 8.8% 28 8.4% 74 8.6%
 Admitted to ICU/CCU 39 7.4% 33 9.9% 72 8.4%
 Cancer therapy 2 0.4% 2 0.6% 4 0.5%
 Heparin induced thrombocytopenia 0 0.0% 0 0.0% 0 0.0%
Table 2– Comparison of Portuguese and Global demographic and anthropometric characteristics
Surgical Patients at Risk Medical Patients at Risk
Portugal 
(n=525)
Global   
(19,842) P*
Portugal  
(n=335)
Global   
(15,487) P*
Female 51% 51% 1 43% 47% 0.145
Age(median) 68 68 1 75 70 >0.05
BMI,Kg/m2 (median) 26.9 25.9 >0.05 27.4 26.0 >0.05
Hospital admission to survey day, days 
(median) 6 5 >0.05 8 6 <0.05
*p estimated from aggregated data
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surgical patients. 
Of 3,145 beds assessed, 2,183 were considered 
eligible. A total of 1,886 patients were assessed (297 
empty beds); with 1,632 patients meeting all criteria. 
The reasons for exclusion were insufficient age (119), 
missing charts (47), displaced patients (26) age less than 
18 years old, missing essential data (23), VTE treatment 
(19) and testing or minor operations (20). Excluding 
missing and inadequate data, the total number of patients 
assessed was 1,651. Of these, 19 were admitted for 
VTE treatment, and consequently excluded from the 
study. Considering the 1,632 enrolled patients, the 
VTE hospital estimated prevalence was 1.2%, in adult 
selected wards.
Primary Objectives
Of the 1,632 enrolled patients, 762 were on surgical 
wards (47.3%; 95% CI 44.9%-49.7%), with 525 deemed 
to be at risk of VTE, according to ACCP guidelines 
(68.9%; 95% CI 65.5%-72.1%), and 870 patients were 
on medical wards (52.7%; 95% CI 50.3%-55.1%), of 
whom 335 (38.5%; 95% CI 35.3%-41.2%) were deemed 
at risk of VTE. The proportion of patients at risk was 
1.8 (surgical/medical).
The number of patients not at risk for VTE, according 
to ACCP, was 772 in the studied population: 237 (31.1%; 
95% CI 27.9%-34.5%) patients in surgical wards; and 
535 (61.5%; 95% CI 58.25-64.7%) patients in medical 
wards.
Pa t ien t  charac te r i s t i c s :  Demographic  and 
anthropometric characteristics of evaluated patients 
and patients at risk of VTE are summarized in Table 1. 
Table 4- Comparison of Portuguese and Global data on the most prevalent 
pathologies in surgery and in medicine wards
At Risk SURGICAL Pts MEDICAL Pts
Malignancy Pulmonary Infection
Portugal 17.1% 45.7%
Global 8.8% 31.2%
p <0.001 <0.001
Table 5– Risk Factors for Bleeding
Patients Surgical Medical All
R
is
k 
fa
ct
or
s f
or
 b
le
ed
in
g 
PR
E
SE
N
T Aspirin on admission 20 3.8% 71 21.2% 91 10.6%
NSAID on admission (excluding aspirin) 39 7.4% 19 5.7% 58 6.7%
Significant renal impairment 21 4.0% 23 6.9% 44 5.1%
Bleeding at hospital admission 25 4.8% 9 2.7% 34 4.0%
Low platelet count (<100,000 per ul) 8 1.5% 17 5.1% 25 2.9%
Hepatic impairment (clinically relevant) 10 1.9% 15 4.5% 25 2.9%
Intracranial hemorrhage 10 1.9% 12 3.6% 22 2.6%
Active gastroduodenal ulcer 7 1.3% 2 0.6% 9 1.0%
Known bleeding disorder (congenital or acquired) 3 0.6% 5 1.5% 8 0.9%
Secondary Objectives:  52.7% (860) of patients at risk received prophylaxis according to ACCP guidelines (Table 6).
Table 6-Patients at risk of VTE and type of prophylaxis administered
Population Surgical(762) Medical(870)
 n % n %
Patients at Risk of VTE 525 68.9% 335 38.5%
None (Omission of Px) 206 39.2% 130 38.8%
Any anticoagulant 312 59.4% 203 60.6%
ACCP recommended prophylaxis 310 59.0% 193 57.6%
Contraindications to Anticoagulant Px 42 8.0% 36 10.7%
Patients at risk without contraindications for Px 483 92.0% 299 89.3%
Appropriate Px (ACCP) 310 64.2% 193 64.5%
n % n %
Patients with no Risk of VTE 209 27.4% 518 59.5%
None (no Px) 126 60.3% 296 58.8%
Any anticoagulant : Inappropriate Px (ACCP) 83 39.7% 207 39.9%
LMWH 79 95.2% 186 89.9%
UFH 2 95.7% 7 3.4%
Vit. K antagonist 5 6.0% 26 12.6%
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The median age of patients at risk for VTE in surgical 
wards was 68 (IQR 54-77) years, median BMI was 26.9 
(IQR 23.4-29.3) kg/m2, and 263 (50.5%) were women. 
The median age of patients in medical wards judged 
to be at risk for VTE was 75 (IQR 63-83) years old, 
median body mass index (BMI) was 27.4 (IQR 22.9-
29.3) kg/m2, and 144 (43.2%) were women. 
For the total population at risk, the median length of 
hospital stay up to survey date was 7.0 (IQR 3.0-14.0) 
days; 6.0 (2.0-13.0) days for those in surgical wards, and 
8.0 (IQR 4.0-14.0) days for patients in medical wards.
No difference was found in gender, age or BMI 
between the Portugal and Global demographics (Table 
2). Only the hospital length of stay to survey was 
statistically significant (p<0.05) in medical patients. 
This value of p was obtained from aggregated data.
Risk Factors
The five most frequent clinical conditions prior to 
hospital admission were chronic pulmonary disease, 
chronic heart failure, obesity, venous insufficiency 
and long term immobility (Table 3). Also observed at 
admission were other medical conditions (in 33.0% of 
surgical patients) and pulmonary infection (in 45.7% of 
medical patients). Malignancy played a more important 
role in surgical than in medical patients, 17.1% vs. 8.3% 
(p<0.001).
The most striking risk factor during the current 
inpatient episode was complete immobilization (29.9%), 
and a partial immobilization (with bathroom privileges) 
ACCP Px  Surgical Conditions
48.0%
80.0%
57.0%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%
Uro-Gynecological
(73)
General and
Digestive Tract
(240)
Ortho Trauma
(115)
  
Parcially aproppriate Px (n) 
Hip replacement (n=24) 1 
Hepatobiliar (n=25) 3 
Other surgery (n=127) 4 
 
Fig. 3– Prophylaxis administered to surgical patients, by type of surgery and VTE risk (%)
Fig. 4– Prophylaxis administered to medical patients, by conditions present during hospital admission and VTE risk (%)
The majority (58.5%; 57.0%) of patients who received prophylaxis were treated with LMWH (Table 7).
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(10.9%), which accounted for an overall prevalence of 
40.8%.
No difference was found between the Portuguese and 
Global patients’ profile risk for VTE, except for the most 
prevalent risk factors in surgical and medical patients, 
malignancy and pulmonary infection (p <0.001).
Contraindication to pharmacological prophylaxis
Risk factors for bleeding11, are reported in Table 
5. Some patients did have multiple risk factors. 42 
surgical at risk patients (8.0%) and 36 medical at risk 
patients (10.7%) had contraindications and restrictions 
for pharmacological prophylaxis (Table 6).
Surgical patients
Any anticoagulant was prescribed to 59.4% (312) 
of surgical patients deemed to be at risk of VTE and 
recommended prophylaxis was applied to 59.0% of 
patients (310). Prophylaxis was provided to 48% of 
uro-gynecological, 57% of general and digestive tract 
surgery and 80% of ortho trauma surgery patients 
(Figure 3).
Medical Patients
Any anticoagulant was prescribed to 60.6 % (203) 
of medical patients deemed to be at risk of VTE, and 
57.6% (193) were prophylaxed according to ACCP 
recommendations. Prophylaxis was provided to 60.2% 
of cardiovascular diseases, to 61.4% of infectious 
diseases, to 55.2% of malignancy patients, and to 41.4% 
of neurologic diseases (Figure 4). 
The majority (58.5%; 57.0%) of patients who 
received prophylaxis were treated with LMWH (Table 
7).
Patients with no risk of VTE (ACCP)
37.6% (290) of patients considered not to have 
evidence for VTE risk, were also prophylaxed with any 
anticoagulant, which was considered to be inappropriate 
(InP); 39.7% (83) of surgical patients, and 39.9% (207) of 
medical patients (Table 8).
No indication was found of the use of mechanical 
pneumatic devices for intermittent compression. Graduated 
compression stockings were used as the sole prophylaxis in 
6 surgical patients at risk, and as an adjuvant prophylaxis in 
a further 16. It was also used in 4 medical patients at risk 
of VTE, and in 22 medical patients with no risk.
DISCUSSION
The ENDORSE study emphasizes the relevance of the 
theme10, the worldwide distribution of hospital patients 
at risk, as well as evidence for the most advantageous 
strategies12.
The hospitals selected for Portugal (Pt) seem to 
adequately represent the country’s hospital framework for 
the purposes of the present study.
We found a prevalence of 1.2% of the exclusion criteria 
treatment of VTE in selected wards. One could assume 
that this would be mainly related to pulmonary embolism, 
given that deep vein thrombosis alone is consensually13-15 
and normally treated in the outpatient clinic, and only the 
serious cases are admitted as inpatients.
The proportion of patients at risk (surgical vs. medical) 
was 1.3 in the Global ENDORSE data and 1.6 (p <0.001) of 
the Portuguese study population. In terms of the proportion 
of hospital adult patients at VTE risk, Portugal (52.7%) 
is ranked fourth of 15 European countries, behind Spain 
Table 7– Type of prophylaxis administered to surgical and medical patients
Type of VTE Prophylaxis  in 
Surgical and Medical Patients  (n=1587 )
Surgical Medical 
at Risk (n=525) no Risk (n=209) at risk  (n=335) no risk  (n=518)
Any anticoagulant 59,4% 39,7% 60,6% 39,4%
Low molecular weight heparin 58,5% 37,8% 57,0% 35,9%
Unfractionated heparin 1,0% 1,0% 0,0% 0,0%
Vitamin K antagonist 1,0% 2,4% 42,0% 50,0%
Graduated compression stockings 3,0% 0,5% 0,9% 2,5%
None 39,2% 60,3% 38,8% 57,1%
Table 8– Type of prophylaxis administered to surgical and medical patients
Type of VTE Prophylaxis 
in 
Surgical and Medical 
Patients  (n=1587 )
Surgical Medical 
at Risk 
(n=525)
no Risk 
(n=209)
at risk 
 (n=335)
no risk 
(n=518)
Any anticoagulant
59,4% 39,7% 60,6% 39,4%
Low molecular 
weight heparin 58,5% 37,8% 57,0% 35,9%
Unfractionated 
heparin 1,0% 1,0% 0,0% 0,0%
Vitamin K 
antagonist 1,0% 2,4% 42,0% 50,0%
Graduated 
compression 
stockings 3,0% 0,5% 0,9% 2,5%
None
39,2% 60,3% 38,8% 57,1%
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(61.3%), Germany (55.6%), and Bulgaria (54%)10.
Comparison of the demographics of the Portuguese 
study population with the Global data revealed (Table 2) 
that Portuguese medical patients are older (75 vs.70), with 
higher BMI (27.4 vs. 26), and they stay longer in hospital 
(8 vs. 6), though the first two differences from Global 
surgical patients are not statistically significant. This is 
quite interesting, since only 38.5% of the medical patients 
were at risk16. This appears to be controversial, (medical 
patients are old), and a reason for further investigation, 
given that age is itself an independent risk factor17,18, and 
the median age of the medical population was 75. There 
was no demographic difference in surgical population 
and in general profile between Portuguese and Global 
ENDORSE patients.
Even so, the prevalence of risk factors before 
hospitalization was similar to the Global Endorse data, 
as well as to other studies10,19. At admission, the main 
risk factors were other medical conditions in surgical 
patients and pulmonary infections in medical patients. 
The prevalence of malignancy in surgical patients was 
17.0% in Portugal vs. 8.8% in Endorse Global (p <0.001). 
Why is there such a difference (more than double) in 
malignancy prevalence in surgical patients? Based on the 
National Hospital Database Report, most of the medical 
patients are followed in outpatient clinics and in day care 
services. As inpatients, either they are admitted for surgical 
treatment, or they stay in specialized oncology hospitals not 
considered in the present study. Immobilization is naturally 
the prevalent additional risk factor during hospital episodes 
(60.6%), as stated in other studies20
In some studies, findings of incorrect prophylaxis4,21have 
been reported. 
From the Portuguese data, we can distinguish two 
groups: 
The at risk patients provided with appropriate 
prophylaxis and the patients not at risk who were 
administered with inappropriate, unnecessary, prophylaxis.
In addition to prophylaxis not being provided to at 
risk patients (39.2% surgical; 38.8% medical), (Table 6), 
it is most striking that the rate omission of prophylaxis 
in patients at risk is the same as the rate of not at risk 
patients supposedly wrongly exposed to pharmacological 
prophylaxis, leading to an increased risk of bleeding, 
among others, and increased costs. Is this just compliance 
with guidelines or are medical patients, (a very small 
proportion at risk 38.5%, vs the burden of pathology and 
age for example), at a much higher risk, not validated by 
risk assessment in medical populations? These results could 
reflect a clinical adjustment to real risks, or indicate the 
existence of real risk factors in patients less than 40 years 
old, with the results reflecting a clinically correct decision. 
This is not a new phenomenon, having been reported 
several times12,21,22.
Of 123,304 hospital admissions from 2001 to 2005 in 
the Health Facts Database (Cerner Corporation, Kansas 
City, MO), only 15.3 % of the patients with at risk medical 
conditions received prophylaxis according to 6th ACCP 
consensus guidelines23.
We find less insufficient prophylaxis in surgical wards 
than in medical ones. Is this a result of stricter criteria for 
evaluation, consistently explained in guidelines, being more 
suitable for surgical patients? Alternatively, the approach 
to medical patients is misleading or unclear, leading to 
inaccurate prophylaxis and misjudgment of whom is 
at risk? Nevertheless, it is evident that prophylaxis has 
increased during the last 10 years and that there is a better 
awareness among the medical community of the benefit 
of good practice (VTE prophylaxis). No single strategy 
for improvement of VTE prophylaxis is sufficient24. There 
must be simple, objective tools (electronic or otherwise), 
incorporated in the clinical evaluation of the patient.It should 
be as easy to apply as those used for diabetes or hypertension. 
In the era of decision-making processes, risk assessment 
models (RAM) adjusted to population25, are key tools for 
targeting individual risk, able to provide better and supported 
treatment choices to physicians. In a recent review26, Frank 
Michota presents arguments about the difficulties and 
problems regarding the gap between evidence and practice 
in VTE prophylaxis. Quality is improving, as key opinion 
leaders, academic and professional groups and associations 
as well as national organizations, highlight the benefits and 
achievements of standards of care27.
According to a current aphorism, it is very important, 
but not enough to look to the forest. This kind of action 
has been taken for some years, with impressive results. In 
2001, a study of 330 US hospitals found prophylaxis to be 
administered to 26% of patients at risk. In 2004 they found 
the prophylaxis rate to be 33%28. The recent IMPROVE 
study5 showed a rate of pharmacological and or mechanical 
VTE prophylaxis in hospital of 50% and ENDORSE 
has found a 50% prophylaxis rate in a much wider and 
heterogeneous data set10. It is now time to look up to the 
tree itself and acknowledge individual characteristics in 
tailoring the appropriate treatment for prevention of disease. 
The responsibility to the patient is individual, not collective. 
Surely, new clinical studies will give appropriate answers to 
these questions despite some concerns about evidence-based 
practice. If we want more evidence-based practice, we need 
more practice-based evidence, (Lawrence Green).
Limitations of the Portuguese ENDORSE study: 
Portuguese data reflect the problems of a cross-sectional 
epidemiological study related to a defined moment in time, 
with no further evaluation of duration of prevention, a 
key issue to validate the accuracy of thromboprophylaxis. 
Evaluations of charts are restrictive but data reflect the 
quality of clinical patient charts. It was found that the 
number of patients on mechanical compression stockings is 
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underestimated, since this item was recorded only when the 
doctor prescribed it on the chart. In Portugal, this procedure 
is considered a service protocol in orthopedics, neurosurgical 
and other areas, and applied directly by nurses without the 
need for prescription.
CONCLUSION
Despite disparities between populations (social, 
economic and ethnic), the Portuguese results are quite 
similar to Global findings. There is still a lack of concern 
in Portugal that thromboembolic events may occur in 
hospitalized patients, a prone group for developing 
Hospital-related VTE. The Portuguese ENDORSE findings 
demonstrate the high prevalence of patients at risk for VTE 
and the need to adjust the use of VTE prophylaxis, validating 
data to assume a national task force for a better practice, 
avoiding preventable deaths and poor long term outcomes.
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